RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer

Clinical Cancer Research

Volumn 15, Issue 8, 2009, Pages 2612-2619

  Cho, Hee Jun ^a   Baek, Kyoung Eun ^a   Park, Sun Mi ^a   Kim, In Kyu ^a   Choi, Yeong Lim ^a   Cho, Hye Jung ^a   Nam, In Koo ^a   Hwang, Eun Mi ^b   Park, Jae Yong ^b   Han, Jae Yoon ^c   Kang, Sang Soo ^c   Kim, Dong Chul ^b   Lee, Won Sup ^d   Lee, Mi Ni ^e   Oh, Gootaeg ^a   Kim, Jae Won ^a   Lee, Chang Won ^a   Yoo, Jiyun ^a,f  

^a Gyeongsang National University   (South Korea)

^b Department of Physiology ^*  (South Korea)

^c School of Medicine

^d Gyeongsang National University School of Medicine   (South Korea)

^e Ewha Womans University   (South Korea)

^f Gyeongsang National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; RHO GDP DISSOCIATION INHIBITOR 2; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEOMICS; STOMACH CANCER;

ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE KNOCKDOWN TECHNIQUES; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; PROTEOMICS; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEINS;

EID: 65249157082     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2192     Document Type: Article

References (39)

1. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003;3: 55-63.
2. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002;2:133 -42.
3. Lozano E, Betson M, Braga VM. Tumor progression: small GTPases and loss of cell-cell adhesion. Bioes- says 2003;25:452 -63.
4. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev1997;11:2295 -322.
5. Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Bio- chemJ 2005;390:1 -9.
6. DerMardirossian C, Bokoch GM. GDIs: central regulatory moleculesin Rho GTPase activation. Trends Cell Biol 2005;15:356 -63.
7. Hart MJ, Maru Y, Leonard D, Witte ON, Evans T, Cerione RA. A GDP dissociation inhibitor that serves as a GTPase inhibitor for the Ras-like protein CDC42Hs. Science 1992;258:812 -5.
8. Chuang TH, Xu X, Knaus UG, Hart MJ, Bokoch GM. GDP dissociation inhibitor prevents intrinsic and GTPase activating protein-stimulated GTP hydrolysis by the Rac GTP-binding protein. J Biol Chem 1993; 268:775-8.
9. Fukomoto Y, Kaibuchi K, Hori Y, et al. Molecularcloning and characterization ofa novel type ofregulatory protein (GDI) for the Rho proteins, ras p21-like small GTP-bindingproteins. Oncogene1990;5:1321 -8.
10. Scherle P, Behrens T, Staudt LM. Ly-GDI, a GDP- dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc Natl Acad Sci U S A1993;90:7568-72.
11. Zalcman G, Closson V, CamonisJ, et al. RhoGDI-3 is a new GDP dissociation inhibitor (GDI). Identification of a non-cytosolic GDI protein interacting with the small GTP-binding proteins RhoB and RhoG. J Biol Chem 1996;271:30366 -74.
12. Lelias JM, Adra CN,Wulf GM, et al. cDNAcloning of a human mRNA preferentially expressed in hematopoietic cells and with homology to a GDP-dissocia- tion inhibitor for the rho GTP-binding proteins. Proc Natl Acad Sci U S A1993;90:1479 -83.
13. Adra CN, Manor D, Ko JL, et al. RhoGDIγ:a GDP- dissociation inhibitor for Rho proteins with preferential expression in brain and pancreas. Proc Natl Acad Sci U S A1997;94:4279 -84.
14. Jones MB, Krutzsch H, Shu H, et al. Proteomicanal- ysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002;2:76 -84.
15. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 2002;87:635-44.
16. Jiang WG,Watkins G, Lane J, et al. Prognostic value of Rho GTPases and Rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 2003;9:6432-40.
17. Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 2001;128:1 -6.
18. ZhangY, Zhang B. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. Cancer Res 2006;66:5592 -8.
19. Gildea JJ, Seraj MJ, Oxford G, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002;62:6418-23.
20. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF, Jr. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 2004;10:3800-6.
21. Lim BH, Cho BI, KimYN, Kim JW, Park ST, Lee CW. Overexpression of nicotinamide N-methyltransferase in gastric cancer tissues and its potential post-transla- tional modification. Exp Mol Med 2006;38:455 -65.
22. Park JG, Frucht H, LaRocca RV, et al. Characteristics of cell lines established from human gastric carcinoma. Cancer Res1990;50:2773 -80.
23. Park JG,Yang HK, Kim WH, et al. Establishment and characterization of human gastric carcinoma cell lines. IntJ Cancer1997;70:443 -9.
24. Lee DH, Yang Y, Lee SJ, et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasmino- gen activator system. Cancer Res 2003;63:4648-55.
25. 6 integrins in invasion. J Cancer Res Clin Oncol 1997; 123:310-6.
26. Yin L, Schwartzberg P, Scharton-Kersten TM, Staudt L, Lenardo M. Immune responses in mice deficient in Ly-GDI, a lymphoid-specific regulator of Rho GTPases. Mol Immunol 1997;34:484-91.
27. Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis 2000;18:519 -25.
28. Detmar M. Tumor angiogenesis. J Investig Dermatol Symp Proc 2000;5:20-3.
29. Takaishi K, Kikuchi A, Kuroda S, et al. Involvementof Rho p21 and its inhibitory GDP/GTP exchange protein (RhoGDI) in cell motility. Mol Cell Biol 1993;13:72-9.
30. Bromberg Y, Shani E, Joseph G, et al. The GDP- bound form of the small G protein Rac1 p21is a potent activator of the superoxide-forming NADPH oxidase of macrophages. J Biol Chem 1994;269:7055 -8.
31. Lin Q, Fuji RN, Yang W, Cerione RA. RhoGDI is required for Cdc42-mediated cellular transformation. Curr Biol 2003;13:1469 -79.
32. Groysman M, Hornstein I, Alcover A, Katzav S.Vav1 and Ly-GDI two regulators of Rho GTPases, function cooperatively as signal transducer inTcell antigen receptor-induced pathways. J Biol Chem 2002;277: 50121 -30.
33. Schunke D, Span P, Ronneburg H, et al. Cyclooxy- genase-2 is a targetgene of Rho GDP dissociation inhibitor h in breast cancer cells. Cancer Res 2007;67: 10694-702.
34. Yiu GK,TokerA. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxyge-nase-2. J Biol Chem 2006;281:12210-7.
35. LarkinsTL, Nowell M, Singh S, Sanford GL. Inhibition ofcyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 2006;6:181.
36. Minn AJ, Guopta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
37. CaoY, Linden P, FarneboJ, et al.Vascularendothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A1998;95:14389-94.
38. Su JL, Yang PC, Shih JY, et al. The VEGF-C/Flt-4 promotes invasion and metastasis of cancer cells. Cancer Cell 2006;9:209-23.
39. Jeltsch M, Kaipainen A, JoukovV, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science1997;276:1423-5.